[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523396":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":46,"collaborators":19,"id":49,"slug":19,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":30,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cisplatin","EXPERIMENTAL","Cisplatin 25 mg\u002Fm2, ivgtt, 30 min, D1, 8.",[13],"Drug: Cisplatin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Cisplatin 25 mg\u002Fm2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Ying Yang, MD","CONTACT","86 64175590","1307","yangying@fudanpci.org",[28],{"facility":29,"status":30,"city":31,"state":19,"zip":19,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Shanghai Cancer Center","RECRUITING","Shanghai","China","CN",{"type":35,"coordinates":36},"Point",[37,38],121.45806,31.22222,{"lat":38,"lon":37},[41,43],{"name":22,"role":23,"phone":42,"phoneExt":25,"email":26},"86 21 64175590",{"name":44,"role":45,"phone":19,"phoneExt":19,"email":19},"Guopei Luo, MD","PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Guopei Luo","Professor","100523396",false,"NCT06095141","Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","Cisplatin Based Regimen to Patients With Advanced Pancreatic Cancer and Homologous Recombination Deficiency","PTCA199-6","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Age ≥ 18 years and ≤ 80 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Histologically or cytologically confirmed advanced pancreas adenocarcinoma.\n* Tumor progression after at least one line of chemotherapy.\n* Genetic or molecular test confirmed the presence of homologous recombination deficiency.\n* Presence of at least of one measurable lesion in agreement to RECIST criteria.\n* The expected survival ≥ 3 months.\n* Adequate organ performance based on laboratory blood tests.\n* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\n\nExclusion Criteria:\n\n* Pregnant or nursing women.\n* Primary pancreatic cancer.\n* Patients who have received platinum or PARPi treatment.\n* The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.\n* Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.\n* Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results.\n* Renal insufficiency or dialysis\n* Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.\n* Patients who are allergic to cisplatin or other platinum drugs.\n* Patients who are unwilling or unable to comply with study procedures.","ALL","18 Years","80 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE2","PHASE3","The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.",[68,69],"Pancreatic Adenocarcinoma","Homologous Recombination Deficiency","2025-08-04",{"date":72,"type":73},"2025-08-07","ACTUAL",{"date":75,"type":73},"2023-12-01",{"date":77,"type":61},"2026-10-31",{"name":5,"class":6},1]